330792-76-2

Usage

Uses

Used in Organic Synthesis:
2-Phenoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine is used as a reagent in organic synthesis for its ability to facilitate the creation of various organic compounds. Its unique structure allows it to participate in a range of chemical reactions, making it a versatile component in the synthesis of complex molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-Phenoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine serves as a building block for the development of pharmaceuticals. Its incorporation into drug candidates can potentially enhance their efficacy and selectivity, contributing to the advancement of new therapeutic agents.
Used in Chemical Research:
2-Phenoxy-5-(4,4,5,5-tetramethyl-[1,3,2]
dioxaborolan-2-yl)-pyridine is utilized in chemical research as a tool to explore novel reactions and mechanisms. Its unique structural elements can provide insights into new pathways and interactions within chemical systems, furthering the understanding of chemical processes.
Used in Drug Discovery:
2-Phenoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine is used in drug discovery for its potential to contribute to the design of new pharmaceuticals. Its presence in molecular structures can influence the pharmacokinetics and pharmacodynamics of drug candidates, making it a valuable component in the development of innovative treatments.
Used in Pharmaceutical Applications:
In the pharmaceutical industry, 2-Phenoxy-5-(4,4,5,5-tetramethyl-[1,3,2] dioxaborolan-2-yl)-pyridine may be used as an active pharmaceutical ingredient or as a key intermediate in the synthesis of drug molecules. Its potential biological activity and structural properties can be harnessed to create medications with specific therapeutic targets.
Used in Agrochemical Applications:
2-Phenoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine may also find utility in the agrochemical sector, potentially serving as a component in the development of pesticides, herbicides, or other agricultural chemicals where its biological activity could be beneficial for crop protection or enhancement.

Upstream product

• 73183-34-3 bis(pinacol)diborane 
• 59717-96-3 5-bromo-2-phenoxypyridine 
• 766-11-0 5-bromo-2-fluoropyridine 
• 108-95-2 phenol 
• 624-28-2 2,5-dibromopyridine 

Downstream Products

• 1558038-57-5 C₁₅H₁₁N₅O 

Relevant academic research and scientific papers

Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma

Ibrutinib (IBN), a first-in-class BTK-inhibitor, was approved by the FDA for the treatment of mantle cell lymphoma (MCL). Although IBN shows excellent performance as an anti-lymphoma agent, it has some undesirable side effects due to its off-target activities. Our studies yielded a novel series of 3-(6-phenoxypyridin-3-yl)-4-amine-1H-pyrazolo[3,4-d]pyrimidine derivatives capable of potent inhibition of Bruton's tyrosine kinase (BTK). Notably, compound 13e explained potent BTK inhibitory activity and could completely inhibit the phosphorylation of BTK and PLCγ2 in Z138 cells at low micromolar concentration. Compared with IBN, compound 13e improved anti-proliferative activities 3–40 folds in MCL cell lines with IC50 values lower than 1 μM. Low micromolar doses of 13e could induce strong cell apoptosis in Jeko-1 and Z138 cells. In addition, compound 13e showed greater BTK selectivity and higher stability in human liver microsomes than IBN and potential safety improvement for the treatment of MCL.

1, 3-di-substituted-4-amino pyrazolopyrimidine compound, preparation method thereof and application of compound

The invention relates to a 1, 3-di-substituted-4-amino pyrazolopyrimidine compound, a preparation method thereof and an application of the compound. The compound is provided with a structure as shownin a formula I. The invention further relates to a preparation method of the compound with the structure as shown in the formula I and a medicine composition. The invention further provides an application of the compound and pharmaceutically acceptable salt thereof to preparation of MCL (mantle cell lymphoma) resistance medicines.

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

BRUTON'S TYROSINE KINASE INHIBITORS

Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I).

SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE

Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).

Pyrazolopyrimidines as therapeutic agents

The present invention is directed to pyrazolopyrimidine derivatives of formula (I) wherein the substituents are defined herein, which are useful as kinase inhibitors and as such are useful for affecting angiogenesis and diseases and conditions associated with angiogenesis.

Pyrazolopyrimidines as therapeutic agents

The present invention provides compounds of Formula I, including pharmaceutically acceptable salts and/or prodrugs thereof, where G, R2, and R3 are defined as described herein.